暗盤前瞻 | 微泰醫療一手中籤率80%，新股情緒何時轉向？
uSMART盈立智投10月18日消息，微泰醫療-B（02235）今日公佈中籤結果，並將於16:15-18:30進行暗盤交易。
小結
新股市場對於未盈利生物公司的反應仍然比較冷淡，微泰醫療的認購情況也不理想，公開和國配的認購倍數都是個位數，不過從認購人數來看，相較和譽有所回暖，有近1.5萬人。微泰醫療本次發行的是H股，港股市值約19.4億港元，基石認購比例約62%，則可流通市值約7.4億港元左右。
近期上市的醫療器械類新股表現不佳，如堃博醫療、先瑞達醫療、心瑋醫療，累計跌幅都達到了40%，在市場情緒方面不利。但由於參與散戶不多，在無回撥以及基石鎖定大額股份的情況下，穩價機制可發揮較大作用，如和譽、創勝集團，首日大幅下跌後的當日或次日股價都能拉回到發行價附近並維持穩定，但股價具體走勢也取決於穩價人的護盤風格，和譽、創勝的穩價人分別爲摩根士丹利、高盛。
配售簡況
1、發售價：30.5港元，爲招股價區間27.7-31.15港元的中上限
2、上市市值：129.18億港元
3、一手市值：3050港元，每手100股
4、有效申購人數：14360名，甲組14335名，乙組25名
5、實際中籤人數：12618名，中一手的爲9132名
6、中籤概況：一手中籤率80.01%，申購2手穩中1手，甲尾中120手（36.6萬港元），乙頭中236手（約72萬港元），頂頭槌3張
7、公開認購倍數：6.79倍，甲組3.99倍，乙組9.58倍
8、國際發售：認購4.9倍，107名承配人，前25大承配人認購股份數佔國配的111.41%
9、回撥情況：公開佔比10%，國配佔比90%
10、基石投資者：11名，共認購61.7%發售股份
11、超額配股權：國際發售已超額分配952.94萬股股份，佔發售股份的15%
12、穩定價格操作人：高盛，穩價結束日爲2021年11月10日
注：以上佔比均假設超額配股權未獲行使
分配基準
股權集中度
基石投資者
現有股東承配人/關聯客戶
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
